|
NCI Trial CDR0000562261
Does anyone know anything about NCI trial CDR0000562261? Has anyone participated? The objective of this trial is:
To determine if the GP2 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-positive, HER2/neu-positive, node-positive, or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, sargramostim (GM-CSF), alone.
To determine if the AE37 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-negative, HER2/neu-positive, node-positive or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, GM-CSF, alone.
I am trying to be proactive. I finished 28 rads almost a week ago (ouch) and will finish Herceptin on 12/28/12.
I am attaching the link:
http://www.cancer.gov/clinicaltrials...thprofessional
__________________
 Found lump by self-exam 10/14/11
HER2neu +/Estrogen +/progesterone -
Grade III poorly differentiated
R side modified radical mastectomy on 12/09/11 with immediate reconstruction (expander)
Stage IIB 2 nodes + out of 10 removed
Double power port inserted 1/11/12
Chemo therapy (TCH) - every 21 days for 6 cycles beginning 1/25/12
Finished chemo on 5/21/12
Continue Herceptin only every 3 weeks until 12/28/12 Radiation (28 rads) began 6/26/2012.
Will start Femara after radiation ends (8/03/12)
From: It's Not About the Hair:
"The hope for healing is not born out of a fear of death, but a love of life.This is a very good thing. When people love life more than they fear death, they come to treatment with open hands, open hearts, open eyes.When people fear death more than they love life, they are clinging and clutching and grasping."
|
Linear Mode
